Canine Atopic Dermatitis Market Size
The Canine Atopic Dermatitis Market reached US$ 5.05 billion in 2025 and is expected to reach US$ 11.63 billion by 2033, growing with a CAGR of 10.4% during the forecast period 2026-2033.
Market Scope
| Metrics | Details |
| Market CAGR | 10.4% |
| Segments Covered | By Treatment Type, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Canine Atopic Dermatitis Market Dynamics
The global canine atopic dermatitis market growth is driven by the rise in prevalence of canine atopic dermatitis, rise in awareness about early signs & symptoms of allergic reaction in animals and development of advanced therapeutic methods to control symptoms, rise in pollution associated with allergens level.
Drug-induced severe hypersensitivity reactions are likely to hamper the market growth
Several drugs cause serious adverse reactions which can further alleviate allergic reactions. Improper management of canine atopic dermatitis in terms of dosage, administration of drugs, and drug combination can also hamper the growth of the global market.
Canine Atopic Dermatitis Market Segment Analysis
The monoclonal antibodies segment is expected to hold the largest share in this market segment
The monoclonal antibodies segment is expected to exhibit profitable market growth over the forecast period. The major attributable factors are the rising awareness of and the increasing product approvals.
Lokivetmab is a caninized anti–interleukin-31 (IL-31) mAb developed and licensed by Zoetis. It works by neutralizing soluble IL-31 released primarily by lymphocytes. Lokivetmab is effective against atopic dermatitis and allergic dermatitis in dogs. Furthermore, in 2019, Kindred Biosciences developed a monoclonal antibody, Interleukin-31, to treat canine atopic dermatitis. It completed its pilot study and showed a significant outcome. Hence, advancements in products are expected to influence the market positively.
Canine Atopic Dermatitis Market Geographical Share
North America region holds the largest market share of the global canine atopic dermatitis market
North America is expected to be a dominant region for the canine atopic dermatitis market, owing to increased spending in R&D activities, the high concentration of key players in the market, and the high rate of households with dog ownership in the region. According to the Animal Health Institute, the US animal health industry serves around 640 million food animals and 383 million companion animals.
Canine Atopic Dermatitis Market Competitive Landscape
The global canine atopic dermatitis market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Elanco, Virbac, Toray Industries Inc., Dechra Veterinary Products, Kindred Biosciences Inc., Ceva, Vetoquinol S.A, Novartis AG. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, in October 2020, Virbac received US FDA approval for its CYCLAVANCE (cyclosporine oral solution) USP MODIFIED to control atopic dermatitis in dogs weighing at least 4 lbs (1.8 kg).
Zoetis
Overview: Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. It includes seven product categories: vaccines, anti-infectives, parasiticides, dermatology products, medicated feed additives, animal health diagnostics, other pharmaceuticals.
Product Portfolio: CYTOPOINT is effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
Recent Developments
- March 2026 – Zoetis and Elanco lead biologics-based treatment landscape
Companies like Zoetis and Elanco continue to dominate with monoclonal antibody therapies, reflecting a broader industry shift toward targeted immunotherapy solutions for chronic canine skin diseases. - March 2026 – Monoclonal antibody therapies dominate innovation in veterinary dermatology
Targeted biologics such as IL-31 inhibitors are becoming the standard of care, offering long-lasting itch relief with fewer side effects compared to steroids and immunosuppressants. - February 2026 – Increasing clinical adoption of anti-IL-31 therapies for itch management
Anti-cytokine therapies targeting IL-31 (key itch mediator) are widely adopted in veterinary practice due to rapid symptom relief and improved quality of life in dogs with chronic dermatitis. - February 2026 – Expansion of pipeline biologics and next-generation dermatology drugs
New monoclonal antibody therapies and immunomodulators are entering development pipelines, aiming to improve durability, dosing frequency, and efficacy in severe atopic dermatitis cases. - January 2026 – Rising demand for combination therapies (biologics + topical + oral drugs)
Veterinarians are increasingly using multimodal treatment approaches, combining biologics with topical therapies, antihistamines, and immunomodulators to manage complex or severe cases. - January 2026 – Growth in veterinary dermatology specialization and diagnostic capabilities
Improved diagnostic tools and increased availability of veterinary dermatologists are enhancing early detection and personalized treatment strategies for canine atopic dermatitis.
